Pipeline / 01 · Platforms

Functional Peptide Platform

A library of 20,000+ engineered peptides for membrane penetration, targeted delivery, and biological modulation.

AH-D PEPTIDE · THE LEAD APPROACH Lipid Envelope Antiviral Disruption Intact viral envelope Lipid bilayer enclosing genome AH-D insertion Amphipathic α-helix penetrates membrane Envelope rupture Membrane integrity lost, virus inactivated Broad-spectrum activity demonstrated against Zika, Dengue, Yellow Fever, Chikungunya, West Nile and HIV.
The LEAD™ approach — Lipid Envelope Antiviral Disruption. AH-D peptide inserts into pathogen lipid envelopes, forms selective pores, and ruptures viral particles. Broad-spectrum activity demonstrated against Zika, Dengue, Yellow Fever, Chikungunya, West Nile, and HIV in vitro.
Premise

The problem we are solving.

Most therapeutic molecules fail at the same moment: they cannot reach the cell interior where their target lives. Peptides — short, programmable chains of amino acids — solve this problem when designed correctly. They can cross membranes, carry payloads, and modulate biology with precision that small molecules cannot match.

MACRO HRD maintains a library of over 20,000 functional peptide designs, each characterized for membrane penetration, tissue specificity, and payload-carrying capacity. Within this library is our AH-D peptide — a 27-mer engineered to disrupt pathogen-derived exosomes and facilitate tissue-barrier access for therapeutic payloads.

Approach

How we tackle it.

Peptide design at MACRO HRD is computational first, experimental second. Every candidate is evaluated against four axes: foreignness (immune detectability), HLA-stability (binding retention across populations), context expression (tissue-specific activation), and clonal fraction (reliability of response).

The highest-scoring candidates are then produced as GMP-grade reagents, formulated into delivery systems — lipid nanoparticles, exosomes, or direct topical carriers — and tested against disease-specific targets. The library compounds across programs: a peptide validated for HIV reservoir activation may also prove effective for HPV antigen delivery or glioblastoma blood-brain-barrier penetration.

SCIENTIFIC VALIDATION Origins, breadth, and platform integration. ORIGINS Engineered from HCV NS5A amphipathic α-helix. D-amino acid form provides protease resistance, enhanced stability, and brain penetration. Published in Nature Materials (2018). BROAD-SPECTRUM Disrupts enveloped viruses via LEAD: Zika EC₅₀ 12 nM, Dengue 38 nM, Yellow Fever 98 nM, HIV 45 nM. Selectivity index >300 (CC₅₀ ~63 μM). HIV & EV RELEVANCE Ruptures HIV envelope in vitro (Jackman 2013). Disrupts tumour-derived exosomes that HIV exploits for immune evasion (Shin 2023, Nature Materials). PLATFORM INTEGRATION Upstream enabling adjunct — not a stand-alone curative. Membrane disruption enhances accessibility for downstream trispecific antibody-mediated killing.
AH-D peptide scientific validation across broad-spectrum antiviral activity and platform integration contexts. Origin studies published in Nature Materials; broad-spectrum data referenced from independent academic collaborators.
i.
Computational design
Deep learning prioritization using NeoDisc, NetMHCpan, and pathogen mimicry filters.
ii.
Proteogenomic validation
MS/MS detection of expressed peptides with RNA and protein co-expression confirmation.
iii.
Payload engineering
Coupling with mRNA, LNPs, or exosome-based delivery vehicles for tissue specificity.
iv.
Library expansion
Characterized peptides enter the permanent library and become available across all programs.
Capabilities

What makes this real.

01
20,000+ design library
The largest internally characterized functional peptide library among Asian biotech platforms, continuously expanded through R&D.
02
AH-D peptide
Proprietary 27-mer designed for exosome disruption and blood-brain-barrier facilitation. Central to our GBM and HIV therapeutic programs.
03
Cross-program utility
Peptides validated for one program become available for others — compounding scientific return across the integrated platform.
04
AI-guided selection
GEDM-3DQ evaluates candidates across foreignness, HLA-stability, expression context, and population coverage in real time.
DRUG DELIVERY · LNP CORE TECHNOLOGY Specific organ targeting via tunable LNPs. Lung ζ = +50.2 ± 1.7 mV Cationic LNP for pulmonary epithelium Spleen ζ = −54.8 ± 6.4 mV Anionic LNP for lymphoid targeting CNS BBB-penetrating RVG29-targeted exosome formulation
Drug delivery core technologies — specific organ targeting and higher in-vivo delivery efficacy via proprietary LNP formulations, with lung- and spleen-targeting variants demonstrated in vivo.
Where It Connects

Part of an integrated platform.

01 · Platforms
Multi-Specific Antibody Platform
Tri-specific antibody systems for precision targeting, immune recruitment, and viral escape prevention.
01 · Platforms
Engineered Immune Cells Platform
CAR-like NK systems and γδ T cell therapies for adaptive, MHC-independent elimination of diseased cells.
02 · Infectious Disease
HIV Functional Cure Program
An integrated therapeutic approach combining tri-specific antibodies, CAR-like NK effectors, AH-D peptide activation, and GEDM-3DQ-guided coordination.
⸻ Continue the platform

“The molecule is only as valuable as the target it reaches. We design for the journey, not only the destination.”

See all ventures → Engage with MACRO HRD